Q-omics provides the consensus-scored TNRC6C profile across patient tissues and cancer cell-line models. TNRC6C expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TNRC6C is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, TNRC6C RNA expression shows 25,165 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, BLCA, and GBM as cancer lineages where TNRC6C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNRC6C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNRC6C survival associations across molecular data types. TNRC6C RNA expression shows survival associations in the most cancer types (26), followed by mutation status (10) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNRC6C RNA expression–survival associations across cancer types. High TNRC6C expression shows unfavorable associations in UVM, but favorable associations in BRCA, KIRC, MESO, HNSC and UCS. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for TNRC6C RNA expression.
This table summarizes TNRC6C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TNRC6C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNRC6C shows lower tumor expression in BLCA, KICH, THCA and UCEC and higher tumor expression in LIHC and CHOL. The BLCA box plot shows higher TNRC6C RNA expression in normal versus tumor tissue (log2 FC = −1.497, t-test p = .001).
This table shows molecular features associated with TNRC6C in patient tissues and cancer cell lines. In patient samples, TNRC6C shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TNRC6C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
